RYTHM, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RYTHM, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.28M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $18.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $15.14M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $58.26M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $59.86M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | $12.09M | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.19M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($71.0K) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $4.02M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($31.80M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.23M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | $570.0K | Mar 31, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.26M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($41.75M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($18.65M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($188.17M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($32.47M) | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | ($21.62M) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.34M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($5.07M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($13.02M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($193.33M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($35.07M) | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | ($12.62M) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $743.0K | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $2.30M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.18M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.93M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.35M | Mar 31, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.06M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $7.18M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $16.06M | Mar 28, 2025 |
| FY2022 | Dec 31, 2022 | $73.35M | Nov 28, 2023 |
| FY2022 | Dec 31, 2021 | $30.81M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | $9.83M | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.54M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($11.58M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($30.98M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($72.02M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($30.15M) | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | ($14.78M) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $4.0K | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $59.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.13M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.22M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | $136.0K | Mar 31, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.68M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $54.02M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $45.27M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $69.69M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $182.05M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | $21.84M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.66M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $25.93M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $59.98M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $78.73M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $44.62M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | $28.29M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.02M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $28.09M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | ($14.71M) | Mar 3, 2026 |
| FY2023 | Dec 31, 2022 | ($9.27M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $137.06M | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | ($6.68M) | Mar 31, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.71M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $9.71M | Mar 3, 2026 |
| FY2023 | Dec 31, 2021 | $50.09M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $632.0K | Nov 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($340.80M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($307.31M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($265.80M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($247.15M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($58.98M) | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | ($26.51M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.20M | Mar 3, 2026 |
| FY2024 | Dec 31, 2024 | $31.17M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $434.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $10.46M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $12.01M | Nov 28, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.62M | Mar 3, 2026 |
| FY2024 | Dec 31, 2024 | $10.52M | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | $16.05M | Apr 15, 2024 |
| FY2023 | Dec 31, 2022 | $407.0K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $12.0K | Nov 28, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (40) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (187) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (902) | Apr 15, 2024 |
| FY2021 | Dec 31, 2021 | (1) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | (5) | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (16) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (40) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (187) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (902) | Apr 15, 2024 |
| FY2021 | Dec 31, 2021 | (1) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | (5) | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.15M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 1.95M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 113,416 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 1.04M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 111,035 | Nov 28, 2023 |
| FY2021 | Dec 31, 2020 | 4.21M | Mar 31, 2022 |